The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Publications
Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature.
Journal of chemotherapy (Florence, Italy). 2017;29(2):113-117
Delayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer.
Case reports in oncology. 2011;4(1):186-91
Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings.
AJR. American journal of roentgenology. 2001;176(3):718-20
Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy.
Oncology. 1998;55(4):340-4
Pulmonary infiltrates following administration of paclitaxel.
Chest. 1996;110(1):289-92
Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996;14(4):1071-6
Pneumonitis related to treatment with paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995;13(2):534-5